Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Presentation Material Financial Results for the Six Months Ended January 31, 2026
Non-consolidated Financial Results for the Six Months Ended January 31, 2026 [Japanese GAAP]
StemRIM, First Half Ordinary Profit Loss Narrows, Nov-Jan Ordinary Profit Loss Narrows
StemRIM Announces Patent Registration for Stem Cell Gene Therapy Technology (Development Code: SR-GT1) Aimed at Curative Treatment of DEB
StemRIM Announces Patent Registration (Canada) for the Use of Redasemtide, as an Additional Therapeutic Indication of Cartilage Disorders
StemRIM Announces Completion of Patient Enrollment in the Global Phase 2b Clinical Trial of the Redasemtide for Acute Ischemic Stroke
StemRIM Announces Patent Registration (JP) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication for Fatty L
StemRIM Announces Completion of Payment for Issuance of New Shares as Restricted Stock Compensation
StemRIM, Aug-Oct (1Q) Ordinary Profit Loss Narrows
StemRIM Announces the Formation of a Compensation Committee on a Voluntary Basis
Non-consolidated Financial Results for the Three Months Ended October 31, 2025 [Japanese GAAP]
[Delayed]Presentation Material for Business Plan and Growth Potential
StemRIM Announces Issuance of New Shares as Remuneration for Restricted Stock
StemRIM Announces Patent Registration for Stem Cell Gene Therapy Technology (Development Code SR-GT1) Aimed at Curative Treatment of Dystrophic Epider
StemRIM Announces Patent Registration (US) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication for Psorias
StemRIM Announces Fixed Details of the Issuance of Stock Options to Temporary Employees and External Collaborator
StemRIM Announces Proposal for Approval of Issuance of Stock Options to our Company's Executive Officers, Employees, and External Collaborators
Presentation Material Financial Results for the Fiscal Year Ended July31,2025
StemRIM Announces Fixed Details of the Issuance of Stock Options to Employees
StemRIM Announces Fixed Details of the Issuance of Stock Options to Directors